nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCC2—Spironolactone—dilated cardiomyopathy	0.254	0.356	CbGbCtD
Canagliflozin—ABCC2—Furosemide—dilated cardiomyopathy	0.173	0.244	CbGbCtD
Canagliflozin—ALB—Furosemide—dilated cardiomyopathy	0.108	0.152	CbGbCtD
Canagliflozin—ABCB1—Lisinopril—dilated cardiomyopathy	0.0939	0.132	CbGbCtD
Canagliflozin—ABCB1—Spironolactone—dilated cardiomyopathy	0.0827	0.116	CbGbCtD
Canagliflozin—Diabetic complication—Lisinopril—dilated cardiomyopathy	0.0523	0.29	CcSEcCtD
Canagliflozin—UGT2B4—pericardium—dilated cardiomyopathy	0.0393	0.382	CbGeAlD
Canagliflozin—SLC5A1—cardiac ventricle—dilated cardiomyopathy	0.0101	0.0977	CbGeAlD
Canagliflozin—SLC5A1—myocardium—dilated cardiomyopathy	0.00946	0.0919	CbGeAlD
Canagliflozin—UGT2B4—cardiac ventricle—dilated cardiomyopathy	0.00926	0.09	CbGeAlD
Canagliflozin—UGT2B4—myocardium—dilated cardiomyopathy	0.00871	0.0847	CbGeAlD
Canagliflozin—Diuresis—Furosemide—dilated cardiomyopathy	0.00778	0.0432	CcSEcCtD
Canagliflozin—Polydipsia—Furosemide—dilated cardiomyopathy	0.00778	0.0432	CcSEcCtD
Canagliflozin—Hypovolaemia—Furosemide—dilated cardiomyopathy	0.00778	0.0432	CcSEcCtD
Canagliflozin—SLC5A1—heart—dilated cardiomyopathy	0.0066	0.0641	CbGeAlD
Canagliflozin—UGT2B4—heart—dilated cardiomyopathy	0.00608	0.0591	CbGeAlD
Canagliflozin—Rash erythematous—Spironolactone—dilated cardiomyopathy	0.00579	0.0321	CcSEcCtD
Canagliflozin—SLC5A1—cardiac atrium—dilated cardiomyopathy	0.00565	0.0549	CbGeAlD
Canagliflozin—UGT2B4—cardiac atrium—dilated cardiomyopathy	0.0052	0.0505	CbGeAlD
Canagliflozin—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00435	0.0242	CcSEcCtD
Canagliflozin—Renal failure acute—Spironolactone—dilated cardiomyopathy	0.00348	0.0193	CcSEcCtD
Canagliflozin—Serum creatinine increased—Lisinopril—dilated cardiomyopathy	0.00294	0.0163	CcSEcCtD
Canagliflozin—Urine output increased—Furosemide—dilated cardiomyopathy	0.00218	0.0121	CcSEcCtD
Canagliflozin—Bladder pain—Furosemide—dilated cardiomyopathy	0.00218	0.0121	CcSEcCtD
Canagliflozin—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00201	0.0112	CcSEcCtD
Canagliflozin—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00199	0.0111	CcSEcCtD
Canagliflozin—Polyuria—Furosemide—dilated cardiomyopathy	0.00199	0.0111	CcSEcCtD
Canagliflozin—ALB—heart—dilated cardiomyopathy	0.00192	0.0186	CbGeAlD
Canagliflozin—Thirst—Furosemide—dilated cardiomyopathy	0.00184	0.0102	CcSEcCtD
Canagliflozin—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00178	0.00986	CcSEcCtD
Canagliflozin—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00177	0.00981	CcSEcCtD
Canagliflozin—Cystitis—Lisinopril—dilated cardiomyopathy	0.00175	0.00969	CcSEcCtD
Canagliflozin—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00171	0.00948	CcSEcCtD
Canagliflozin—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00164	0.0091	CcSEcCtD
Canagliflozin—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00164	0.00908	CcSEcCtD
Canagliflozin—Dehydration—Furosemide—dilated cardiomyopathy	0.00163	0.00903	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.0016	0.00887	CcSEcCtD
Canagliflozin—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00151	0.00838	CcSEcCtD
Canagliflozin—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.0015	0.0083	CcSEcCtD
Canagliflozin—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00148	0.00823	CcSEcCtD
Canagliflozin—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00142	0.00789	CcSEcCtD
Canagliflozin—Pollakiuria—Furosemide—dilated cardiomyopathy	0.0014	0.00775	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00138	0.00766	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00136	0.00757	CcSEcCtD
Canagliflozin—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00135	0.00747	CcSEcCtD
Canagliflozin—Urticaria—Spironolactone—dilated cardiomyopathy	0.00126	0.00697	CcSEcCtD
Canagliflozin—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00123	0.00683	CcSEcCtD
Canagliflozin—Dehydration—Lisinopril—dilated cardiomyopathy	0.00122	0.00678	CcSEcCtD
Canagliflozin—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.0012	0.00666	CcSEcCtD
Canagliflozin—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.0012	0.00664	CcSEcCtD
Canagliflozin—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00119	0.00659	CcSEcCtD
Canagliflozin—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00119	0.00658	CcSEcCtD
Canagliflozin—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00116	0.00646	CcSEcCtD
Canagliflozin—Pruritus—Spironolactone—dilated cardiomyopathy	0.00112	0.00621	CcSEcCtD
Canagliflozin—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00111	0.00617	CcSEcCtD
Canagliflozin—Angiopathy—Furosemide—dilated cardiomyopathy	0.0011	0.0061	CcSEcCtD
Canagliflozin—Erythema—Furosemide—dilated cardiomyopathy	0.00105	0.00585	CcSEcCtD
Canagliflozin—Malnutrition—Furosemide—dilated cardiomyopathy	0.00105	0.00585	CcSEcCtD
Canagliflozin—Dizziness—Spironolactone—dilated cardiomyopathy	0.00105	0.0058	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00104	0.00575	CcSEcCtD
Canagliflozin—Rash—Spironolactone—dilated cardiomyopathy	0.000997	0.00553	CcSEcCtD
Canagliflozin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000996	0.00553	CcSEcCtD
Canagliflozin—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000984	0.00546	CcSEcCtD
Canagliflozin—Nausea—Spironolactone—dilated cardiomyopathy	0.000939	0.00521	CcSEcCtD
Canagliflozin—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000897	0.00498	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000891	0.00495	CcSEcCtD
Canagliflozin—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00089	0.00494	CcSEcCtD
Canagliflozin—Dry mouth—Furosemide—dilated cardiomyopathy	0.000878	0.00487	CcSEcCtD
Canagliflozin—Shock—Furosemide—dilated cardiomyopathy	0.000846	0.0047	CcSEcCtD
Canagliflozin—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000844	0.00468	CcSEcCtD
Canagliflozin—Skin disorder—Furosemide—dilated cardiomyopathy	0.000835	0.00464	CcSEcCtD
Canagliflozin—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000824	0.00457	CcSEcCtD
Canagliflozin—Hypotension—Furosemide—dilated cardiomyopathy	0.000804	0.00446	CcSEcCtD
Canagliflozin—Erythema—Lisinopril—dilated cardiomyopathy	0.000791	0.00439	CcSEcCtD
Canagliflozin—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000791	0.00439	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000743	0.00412	CcSEcCtD
Canagliflozin—Fatigue—Furosemide—dilated cardiomyopathy	0.000742	0.00412	CcSEcCtD
Canagliflozin—Constipation—Furosemide—dilated cardiomyopathy	0.000736	0.00408	CcSEcCtD
Canagliflozin—Angioedema—Lisinopril—dilated cardiomyopathy	0.000723	0.00401	CcSEcCtD
Canagliflozin—Syncope—Lisinopril—dilated cardiomyopathy	0.000709	0.00394	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000703	0.0039	CcSEcCtD
Canagliflozin—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000695	0.00386	CcSEcCtD
Canagliflozin—Urticaria—Furosemide—dilated cardiomyopathy	0.000683	0.00379	CcSEcCtD
Canagliflozin—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00068	0.00377	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000669	0.00371	CcSEcCtD
Canagliflozin—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000658	0.00365	CcSEcCtD
Canagliflozin—ABCB1—heart—dilated cardiomyopathy	0.000646	0.00628	CbGeAlD
Canagliflozin—Infection—Lisinopril—dilated cardiomyopathy	0.000641	0.00356	CcSEcCtD
Canagliflozin—Shock—Lisinopril—dilated cardiomyopathy	0.000635	0.00352	CcSEcCtD
Canagliflozin—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000634	0.00352	CcSEcCtD
Canagliflozin—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000627	0.00348	CcSEcCtD
Canagliflozin—Asthenia—Furosemide—dilated cardiomyopathy	0.000617	0.00342	CcSEcCtD
Canagliflozin—Pruritus—Furosemide—dilated cardiomyopathy	0.000609	0.00338	CcSEcCtD
Canagliflozin—Hypotension—Lisinopril—dilated cardiomyopathy	0.000603	0.00335	CcSEcCtD
Canagliflozin—Dizziness—Furosemide—dilated cardiomyopathy	0.000569	0.00316	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000557	0.00309	CcSEcCtD
Canagliflozin—Fatigue—Lisinopril—dilated cardiomyopathy	0.000556	0.00309	CcSEcCtD
Canagliflozin—Constipation—Lisinopril—dilated cardiomyopathy	0.000552	0.00306	CcSEcCtD
Canagliflozin—Rash—Furosemide—dilated cardiomyopathy	0.000542	0.00301	CcSEcCtD
Canagliflozin—Dermatitis—Furosemide—dilated cardiomyopathy	0.000542	0.00301	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000528	0.00293	CcSEcCtD
Canagliflozin—Urticaria—Lisinopril—dilated cardiomyopathy	0.000513	0.00285	CcSEcCtD
Canagliflozin—Nausea—Furosemide—dilated cardiomyopathy	0.000511	0.00284	CcSEcCtD
Canagliflozin—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00051	0.00283	CcSEcCtD
Canagliflozin—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000475	0.00264	CcSEcCtD
Canagliflozin—Asthenia—Lisinopril—dilated cardiomyopathy	0.000463	0.00257	CcSEcCtD
Canagliflozin—Pruritus—Lisinopril—dilated cardiomyopathy	0.000457	0.00253	CcSEcCtD
Canagliflozin—SLC5A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000435	0.0773	CbGpPWpGaD
Canagliflozin—SLC5A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC22A5—dilated cardiomyopathy	0.000435	0.0773	CbGpPWpGaD
Canagliflozin—Dizziness—Lisinopril—dilated cardiomyopathy	0.000427	0.00237	CcSEcCtD
Canagliflozin—Rash—Lisinopril—dilated cardiomyopathy	0.000407	0.00226	CcSEcCtD
Canagliflozin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000407	0.00226	CcSEcCtD
Canagliflozin—Nausea—Lisinopril—dilated cardiomyopathy	0.000383	0.00213	CcSEcCtD
Canagliflozin—ABCC2—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.000249	0.0443	CbGpPWpGaD
Canagliflozin—SLC5A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000198	0.0351	CbGpPWpGaD
Canagliflozin—SLC5A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.000198	0.0351	CbGpPWpGaD
Canagliflozin—UGT1A9—PPARA activates gene expression—ANKRD1—dilated cardiomyopathy	0.000162	0.0288	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—ANKRD1—dilated cardiomyopathy	0.000159	0.0282	CbGpPWpGaD
Canagliflozin—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.000117	0.0208	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—ANKRD1—dilated cardiomyopathy	0.000109	0.0194	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000103	0.0183	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000103	0.0183	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.0001	0.0178	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.0001	0.0178	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.0001	0.0178	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.0001	0.0178	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	9.34e-05	0.0166	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	9.34e-05	0.0166	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—TTN—dilated cardiomyopathy	7.81e-05	0.0139	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—TTN—dilated cardiomyopathy	7.44e-05	0.0132	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ANKRD1—dilated cardiomyopathy	6.79e-05	0.0121	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ANKRD1—dilated cardiomyopathy	6.79e-05	0.0121	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—ACTN2—dilated cardiomyopathy	6.77e-05	0.012	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—ACTN2—dilated cardiomyopathy	6.45e-05	0.0115	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—TAZ—dilated cardiomyopathy	6.38e-05	0.0113	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—TAZ—dilated cardiomyopathy	6.38e-05	0.0113	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—SDHA—dilated cardiomyopathy	5.77e-05	0.0103	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—SDHA—dilated cardiomyopathy	5.77e-05	0.0103	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—VCL—dilated cardiomyopathy	5.76e-05	0.0102	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—VCL—dilated cardiomyopathy	5.48e-05	0.00974	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ANKRD1—dilated cardiomyopathy	5.24e-05	0.00931	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—TAZ—dilated cardiomyopathy	4.93e-05	0.00875	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—SDHA—dilated cardiomyopathy	4.46e-05	0.00792	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	4.36e-05	0.00774	CbGpPWpGaD
Canagliflozin—ALB—Binding and Uptake of Ligands by Scavenger Receptors—CD36—dilated cardiomyopathy	4.21e-05	0.00747	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	4.1e-05	0.00728	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—SOD2—dilated cardiomyopathy	3.8e-05	0.00676	CbGpPWpGaD
Canagliflozin—UGT1A9—PPARA activates gene expression—CD36—dilated cardiomyopathy	3.65e-05	0.00648	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CD36—dilated cardiomyopathy	3.57e-05	0.00634	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—NPPA—dilated cardiomyopathy	3.53e-05	0.00627	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—NPPA—dilated cardiomyopathy	3.53e-05	0.00627	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	3.46e-05	0.00615	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PSEN2—dilated cardiomyopathy	3.42e-05	0.00607	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PSEN2—dilated cardiomyopathy	3.42e-05	0.00607	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	3.32e-05	0.00589	CbGpPWpGaD
Canagliflozin—UGT1A9—PPARA activates gene expression—AGT—dilated cardiomyopathy	3.29e-05	0.00584	CbGpPWpGaD
Canagliflozin—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—AGT—dilated cardiomyopathy	3.22e-05	0.00571	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	3.14e-05	0.00558	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—SOD2—dilated cardiomyopathy	3.09e-05	0.0055	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	3e-05	0.00533	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	2.99e-05	0.00531	CbGpPWpGaD
Canagliflozin—ALB—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	2.96e-05	0.00525	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—GPX1—dilated cardiomyopathy	2.95e-05	0.00524	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	2.88e-05	0.00512	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	2.8e-05	0.00498	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	2.8e-05	0.00498	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	2.79e-05	0.00496	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	2.6e-05	0.00463	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	2.55e-05	0.00454	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—CD36—dilated cardiomyopathy	2.46e-05	0.00438	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CD36—dilated cardiomyopathy	2.46e-05	0.00437	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	2.46e-05	0.00437	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—CD36—dilated cardiomyopathy	2.35e-05	0.00417	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	2.35e-05	0.00417	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	2.34e-05	0.00415	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	2.28e-05	0.00405	CbGpPWpGaD
Canagliflozin—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—AGT—dilated cardiomyopathy	2.22e-05	0.00394	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	2.17e-05	0.00386	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	2.14e-05	0.00381	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	2.1e-05	0.00372	CbGpPWpGaD
Canagliflozin—SLC5A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.04e-05	0.00362	CbGpPWpGaD
Canagliflozin—SLC5A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.04e-05	0.00362	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ANKRD1—dilated cardiomyopathy	1.94e-05	0.00345	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TAZ—dilated cardiomyopathy	1.82e-05	0.00324	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TTN—dilated cardiomyopathy	1.79e-05	0.00317	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—RAC1—dilated cardiomyopathy	1.72e-05	0.00305	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—RAC1—dilated cardiomyopathy	1.72e-05	0.00305	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—SDHA—dilated cardiomyopathy	1.65e-05	0.00293	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GPX1—dilated cardiomyopathy	1.57e-05	0.00279	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GPX1—dilated cardiomyopathy	1.57e-05	0.00279	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ACTN2—dilated cardiomyopathy	1.55e-05	0.00275	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	1.55e-05	0.00274	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CD36—dilated cardiomyopathy	1.53e-05	0.00271	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CD36—dilated cardiomyopathy	1.53e-05	0.00271	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	1.5e-05	0.00267	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	1.5e-05	0.00267	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—TNF—dilated cardiomyopathy	1.44e-05	0.00256	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	1.4e-05	0.00248	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—AGT—dilated cardiomyopathy	1.38e-05	0.00244	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—AGT—dilated cardiomyopathy	1.38e-05	0.00244	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	1.35e-05	0.00241	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	1.32e-05	0.00234	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	1.32e-05	0.00234	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VCL—dilated cardiomyopathy	1.32e-05	0.00234	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	1.22e-05	0.00218	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GPX1—dilated cardiomyopathy	1.21e-05	0.00215	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CD36—dilated cardiomyopathy	1.18e-05	0.00209	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TNF—dilated cardiomyopathy	1.17e-05	0.00208	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—RAF1—dilated cardiomyopathy	1.14e-05	0.00202	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—RAF1—dilated cardiomyopathy	1.14e-05	0.00202	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	1.09e-05	0.00194	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	1.07e-05	0.00191	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—AGT—dilated cardiomyopathy	1.06e-05	0.00189	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	1.03e-05	0.00184	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	1.03e-05	0.00183	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ANKRD1—dilated cardiomyopathy	1.02e-05	0.0018	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	1.01e-05	0.0018	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.01e-05	0.00179	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	9.8e-06	0.00174	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TAZ—dilated cardiomyopathy	9.55e-06	0.0017	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	9.32e-06	0.00166	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	8.9e-06	0.00158	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	8.9e-06	0.00158	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	8.82e-06	0.00157	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—SDHA—dilated cardiomyopathy	8.64e-06	0.00153	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	8.37e-06	0.00149	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—EGFR—dilated cardiomyopathy	7.81e-06	0.00139	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—EGFR—dilated cardiomyopathy	7.81e-06	0.00139	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	7.57e-06	0.00134	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	6.83e-06	0.00121	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	6.73e-06	0.00119	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ITGB1—dilated cardiomyopathy	6.61e-06	0.00117	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.68e-06	0.00101	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CD36—dilated cardiomyopathy	5.64e-06	0.001	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	5.48e-06	0.000974	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RAC1—dilated cardiomyopathy	5.31e-06	0.000943	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.27e-06	0.000936	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	5.16e-06	0.000916	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.13e-06	0.000911	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	4.66e-06	0.000828	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.62e-06	0.000821	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	4.61e-06	0.000819	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPX1—dilated cardiomyopathy	4.48e-06	0.000796	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	4.39e-06	0.00078	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CD36—dilated cardiomyopathy	4.36e-06	0.000775	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—AGT—dilated cardiomyopathy	3.93e-06	0.000698	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RAF1—dilated cardiomyopathy	3.52e-06	0.000626	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.05e-06	0.000541	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.67e-06	0.000474	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPX1—dilated cardiomyopathy	2.35e-06	0.000417	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CD36—dilated cardiomyopathy	2.29e-06	0.000406	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—AGT—dilated cardiomyopathy	2.06e-06	0.000365	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	2.06e-06	0.000365	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CD36—dilated cardiomyopathy	2e-06	0.000356	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—AGT—dilated cardiomyopathy	1.8e-06	0.00032	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	1.27e-06	0.000225	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	1.23e-06	0.000219	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.11e-06	0.000197	CbGpPWpGaD
